The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Busutti M, Cingolani A, Natali F, Mattiotti M, Grandinetti V, Baraldi O, Comai G, Candoli P, La Manna G

Everolimus-associated alveolar hemorrage relapse after drug discontinuation in a kidney transplant recipient.

Journal of nephrology. 2022;35(4):1275-1278

Junpaparp P, Sharma B, Samiappan A, Rhee JH, Young KR

Everolimus-induced severe pulmonary toxicity with diffuse alveolar hemorrhage.

Annals of the American Thoracic Society. 2013;10(6):727-9

Depuydt P, Nollet J, Benoit D, Praet M, Caes F

Fatal acute pulmonary injury associated with everolimus.

The Annals of pharmacotherapy. 2012;46(3):e7

Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS

Diffuse alveolar hemorrhage induced by everolimus.

Chest. 2010;137(2):456-9